印度和瑞士推进了药房合作,旨在为欧洲自由贸易区投资100B美元和100万个就业机会。 India and Switzerland advanced pharma cooperation, aiming for $100B in EFTA investment and one million jobs.

印度和瑞士于2025年11月27日举行了高级别会谈,重点是扩大制药和生物技术合作,包括研究与开发以及增加瑞士对印度保健部门的投资。 India and Switzerland held high-level talks on November 27, 2025, focusing on expanding pharmaceutical and biotechnology cooperation, including research and development and increased Swiss investment in India’s healthcare sector. 联盟商务部长Piyush Goyal会见了瑞士国务秘书Helene Budliger Artida,后者与制药公司代表团一起访问了他。 Union Commerce Minister Piyush Goyal met with Swiss State Secretary Helene Budliger Artieda, who visited with a delegation of pharma firms. 讨论的重点是推动2024年10月生效的《印度-欧洲自由贸易区贸易和经济伙伴关系协定》,其中包括承诺在15年内为欧洲自由贸易区投资1 000亿美元,预计将创造100万个就业机会。 The discussions centered on advancing the India-EFTA Trade and Economic Partnership Agreement, which entered into force in October 2024, and included commitments to $100 billion in EFTA investments over 15 years, expected to create one million jobs. 会议强调,一个专门的欧洲自由贸易区服务台是精简投资的单一窗口平台。 A dedicated EFTA Desk was highlighted as a single-window platform to streamline investment. 双方都强调监管改革、数据保护和扩大制造业,以加强印度的全球制药竞争力,并提供负担得起的医疗解决方案。 Both sides emphasized regulatory reforms, data protection, and scaling manufacturing to strengthen India’s global pharma competitiveness and deliver affordable healthcare solutions.